stockrowAMNEAL PHARMACEUTICALS, INC. (AMRX) vs Neurocrine Biosciences, Inc. (NBIX)
- AMNEAL PHARMACEUTICALS, INC. AMRX 21.28 +5.66%
- Neurocrine Biosciences, Inc. NBIX 169.00 +2.65%
AMNEAL PHARMACEUTICALS, INC. and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $16.7B against $7.0B — 2.4× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 24.2× against 40.4×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 8.88%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs 4.17%) and the higher return on invested capital (17.7% vs 8.45%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 17 and AMNEAL PHARMACEUTICALS, INC. on 4.
Valuation
Profitability
| Metric | AMRX | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 40.24% | 97.78% | 53.51% |
| Operating margin | 14.99% | 23.96% | 0.00% |
| Net margin | 4.17% | 18.98% | (0.73%) |
| Free cash flow margin | (1.89%) | 28.09% | 0.00% |
| Return on equity | (53,107.17%) | 20.41% | (0.02%) |
| Return on assets | 3.01% | 14.20% | (1.64%) |
| Return on invested capital | 8.45% | 17.65% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack